In our upcoming June 2023 Mass Tort Success Course, we will compare the Taxotere Hair Loss litigation with the more recent Taxotere Canalicular Stenosis litigation.
At minimum, we would recommend that you contact your Taxotere Hair Loss Plaintiffs (including any you may have rejected for SOL reasons etc.) and inquire whether the individual suffered from significant eye problems after their Taxotere treatment.
One difference: At trail, Plaintiffs’ counsel will not have to overcome the possibility that juries will misperceive “Canalicular Stenosis” as merely cosmetic.
Our take on the evidence: The maker of Taxotere knew or should have known over twenty years ago that the administration of Taxotere caused significant and often irreversible eye damage. Also, the product maker knew or should have known that other similar chemotherapy products did not present the same risk profile. Despite this knowledge the product maker continued to downplay the risk associated with their massively profitable product, continuing to reap corporate benefits at the expense of vulnerable cancer sufferers.
Results: In three patients receiving weekly docetaxel, canalicular stenosis and resultant epiphora developed shortly after start of their treatment. Discontinuation of drug several months after initiation of therapy did not lead to resolution of symptoms in two of the three patients.
Despite the recommendations from the scientific community that treating physicians monitor patients for canalicular stenosis and discontinue (switch to another product) Taxotere, the maker continued to fail to give such instructions and down played the long term consequences by informing doctors that the constitution was reversible. Indeed, minimizing a warning poses more risk to patients than no warning at all in many cases.
Adequate Warning vs Under Warning
“The fact that the package insert mentioned PTC does not make the warning adequate as a matter of law. See Id. at 853; Stahl v. Novartis Pharms. Corp., 283 F.3d 254 (5th Cir.2002). The drug manufacturer "has discharged its duty to consumers of its prescription drugs when it has reasonably informed prescribing physicians of the dangers of harm from such a drug. Thus, ... a mere reference to an adverse effect is not necessarily an `adequate warning.'" Stahl, 283 F.3d at 266-67 (internal quotation marks and citation omitted).”
The maker of Taxotere appears to have led physicians to believe that risk of Canalicular Stenosis was not significant in the short term and virtually absent long term. Obviously, had the maker issued the warnings and instructions recommended in the literature in 2001, treating doctors would have monitored for the condition and discontinued use of their product. If this had occurred, there would be virtually no clients now in need of representation.
This is a standardised guide to give you an idea of what size you will need, however some brands may vary from these conversions.
Ready to Wear Clothing
Size | XXS - XS | XS - S | S - M | M - L | L - XL | XL - XXL |
---|---|---|---|---|---|---|
UK | 6 | 8 | 10 | 12 | 14 | 16 |
US | 2 | 4 | 6 | 8 | 10 | 12 |
Italy (IT) | 38 | 40 | 42 | 44 | 46 | 48 |
France (FR/EU) | 34 | 36 | 38 | 40 | 42 | 44 |
Denmark | 32 | 34 | 36 | 38 | 40 | 42 |
Russia | 40 | 42 | 44 | 46 | 48 | 50 |
Germany | 32 | 34 | 36 | 38 | 40 | 42 |
Japan | 5 | 7 | 9 | 11 | 13 | 15 |
Australia | 6 | 8 | 10 | 12 | 14 | 16 |
Korea | 33 | 44 | 55 | 66 | 77 | 88 |
China | 160/84 | 165/86 | 170/88 | 175/90 | 180/92 | 185/94 |
Jeans | 24-25 | 26-27 | 27-28 | 29-30 | 31-32 | 32-33 |
Color: Gray
1 X $113.88
Comments (3)